Every 10-Q that Jupiter Neurosciences, Inc. (JUNS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow JUNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JUNS filings page.
Jupiter Neurosciences, Inc. reported results for the six months ended June 30, 2026 as a clinical-stage CNS-focused company with a new consumer supplements line. Net revenues from Nugevia products were modest at $42,897, while the company incurred a net loss of $4,336,355 and used $3,727,022 in operating cash. Cash declined to $1,521,874 from $3,789,342 at December 31, 2025, and accumulated deficit reached $39,003,381.
Management states that recurring losses, negative cash flows, and limited cash raise substantial doubt about the ability to continue as a going concern. To address liquidity, Jupiter relies on a $20.0 million Standby Equity Purchase Agreement, with about $17.2 million remaining available, and completed a $2.0 million registered direct offering at $21.00 per share. Fair value of Yorkville convertible notes fell to $1,528,469, producing a non‑cash gain of $550,380, but interest expense increased materially.
Strategically, Jupiter began a Phase IIa Parkinson’s trial using its JOTROL™ formulation, launched initial Nugevia sales, and signed a definitive license with PharmAla for U.S. rights to ALA‑002, with $3,333,333 in upfront consideration plus significant development and sales milestones. A 1‑for‑75 reverse stock split was effected after quarter‑end in connection with Nasdaq bid‑price compliance efforts.
Jupiter Neurosciences, Inc. reported a first‑quarter 2026 net loss of $2,061,958 on $18,652 of product revenue, reflecting early commercialization of its Nugevia supplement line alongside ongoing R&D spending. Cash was $2,362,749 at March 31, 2026, against total liabilities of $6,732,041 and a stockholders’ deficit of $2,783,457, including an accumulated deficit of $36,728,984.
The company continues to fund operations through equity and convertible debt, notably a Standby Equity Purchase Agreement for up to $20.0 million of common stock and $6.0 million of related convertible notes, which had a fair value of $4,824,411 and principal of $5,527,625 outstanding. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes Nasdaq notifications for non‑compliance with minimum bid price and market value listing requirements, while advancing its JOTROL™ CNS drug pipeline and preparing a Phase IIa Parkinson’s trial.
Jupiter Neurosciences (JUNS) filed its Q3 2025 report, highlighting higher operating spend, a wider loss, and a going‑concern warning. For the quarter ended September 30, 2025, the company posted a net loss of $2,288,034 as research and development rose to $816,697 and general and administrative expenses increased to $1,480,356. For the nine months, net loss was $6,069,866.
Cash was $723,797 as of September 30, 2025, and operating cash outflows totaled $3,045,713 year‑to‑date. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Subsequent to quarter‑end, the company entered a Standby Equity Purchase Agreement for up to $20.0 million and received a $3,720,000 pre‑paid advance via an 8% note convertible at $1.50 per share, subject to a 4.99% beneficial‑ownership cap and a Nasdaq 19.99% exchange cap of 7,180,504 shares unless stockholder approval is obtained. Shares outstanding were 34,294,546 as of September 30, 2025; as of November 14, 2025, 34,426,355 shares were outstanding.